The Efficacy and Toxicity of Lobaplatin-contained Chemotherapy in Extensive-stage Small-cell Lung Cancer

Abstract

To assess the efficacy and toxicity of Lobaplatin (LBP) -contained chemotherapy on extensive stage small-cell lung cancer (ES-SCLC), we conducted a prospective, single-arm, and multicenter Phase IV clinical trial on Lobaplatin (ChiCTR-ONC-13003471), and used the patient clinical data obtained from our cancer center to perform the analysis. Previously untreated patients with ES-SCLC were given LBP intravenously (IV) at 30 mg/m2 on day 1 and etoposide IV at 100 mg/m2 on day 1, 2, and 3. The treatment was cycled every 21 days, lasting for four to six cycles. The patients with second-line treatment or above were also included in the study, and they were treated with LBP-contained regimen: a single dose of LBP at 50 mg/m2 on day 1 through IV; combined application, LBP30 mg/m2 IV on day 1. From May 2015 to August 2016, 36 patients were enrolled in the study at our cancer center. For the 30 first-line patients, the median overall survival (OS) and the median progression-free survival (PFS) was 13.0 months (ranging from 11.2 to 14.7 months) and 4.7 months (ranging from 1.6 to 7.7 months) respectively, with overall response rate of 57 % and disease control rate of 85.7%. For the 6 patients with second-line treatment or above, one patient got a partial response (PR) and four patients got a stable disease (SD). The most frequent drug-related adverse effects were leukopenia and neutropenia, and no grade 3/4 hepatotoxicity or nephrotoxicity was observed. These results indicated that LBP-contained chemotherapy was effective and tolerable for extensive stage SCLC in terms of response and survival. However, due to the small sample size of this study, we need to wait for the OS data of phase Ⅲ clinical trial and the final data of this multicenter Phase IV study to draw the conclusion.

Retrospective study of the efficacy and toxicity of lobaplatin‐etoposide chemotherapy in small cell lung cancer

“…Combination chemotherapy with irinotecan and cisplatin for SCLC leads to equal or better survival than etoposide and cisplatin, with median survival of 9.3–12.8 months . A phase III study of EL in ES‐SCLC patients and other studies on the EL regimen reported median PFS and DCR of 4.7–6.5 months and 69.5–90.4%, respectively, in first‐line treatment . Our results are consistent with the findings of these studies.…”

“…21,22 A phase III study of EL in ES-SCLC patients and other studies on the EL regimen reported median PFS and DCR of 4.7-6.5 months and 69.5-90.4%, respectively, in firstline treatment. [23][24][25][26] Our results are consistent with the findings of these studies. The median PFS and DCR in our study cohort were 6.8 months and 90% in all patients (limited vs. extensive stage: 9.6 vs. 5.9 months, 100% vs. 84%, respectively).…”

Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab

“…Importantly, while nedaplatin led to less gastrointestinal toxicities, nephrotoxicity, ototoxicity, and neurotoxicity compared with cisplatin, more hematologic toxicities such as grade 3/4 neutropenia and thrombocytopenia were seen in nedaplatin-treated patients (7,8). Lobaplatin is another platinum compound showing anti-tumor activity in multiple solid tumors such as breast cancer, small-cell lung cancer, and hepatocellular carcinoma (10)(11)(12). Lobaplatinbased induction chemotherapy followed by lobaplatin-radiotherapy showed comparable survival outcomes but less acute toxicities than cisplatin-based concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma and might be a promising alternative to cisplatin-based treatment (13).…”

<p>Lobaplatin-Based Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastasis from Appendiceal and Colorectal Cancer: Safety and Efficacy Profiles</p>

“…[4][5][6][7] Compared with other traditional platinum drugs, such as cisplatin and carboplatin, lobaplatin, a third-generation alkylating antineoplastic drug, has the advantages of high solubility in water, good stability, wide anticancer spectrum and high antitumor activity. It has been investigated in patients with advanced solid tumors, including gastric cancer, 8,9 colorectal cancer, 10,11 hepatocellular carcinoma, 12,13 small-cell lung cancer, 14 and appendicular osteosarcoma. 15 However, the safety and efficacy of lobaplatin, especially when used in combination with HIPEC for the purposes of treating peritoneal appendiceal and colorectal cancer metastases, remain unclear.…”